FKBP Activators

Featured Inhibitors
Inhibitors (4)
Modulators (2)
Activators (2)
Antagonist (1)

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S9726	Rimiducid (AP1903)	Rimiducid (AP1903) is a chemical protein dimerizer that binds tightly to the target FKBP fusion protein while binding minimally to the abundant natural FKBP. This compound elicits potent and dose-dependent apoptosis of cells in culture expressing dimerizer-dependent Fas constructs, with an EC50 of ≈0.1 nM.	bioRxiv, October 13, 2025, nan Nature Genetics, August 22, 2024, 1914-1924 bioRxiv, 2025, nan
S8317	3BDO	3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signaling pathway. It inhibits autophagy in HUVECs. This compound inhibits oxLDL-induced apoptosis.	Cancer Immunology Research, May 02 2024, 631-643 Journal of Neuroscience, July 15 2020, 5531-5548 Cancer Immunology Research, 2024, 631–643

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S9726

Rimiducid (AP1903)

Rimiducid (AP1903) is a chemical protein dimerizer that binds tightly to the target FKBP fusion protein while binding minimally to the abundant natural FKBP. This compound elicits potent and dose-dependent apoptosis of cells in culture expressing dimerizer-dependent Fas constructs, with an EC50 of ≈0.1 nM.

bioRxiv, October 13, 2025, nan

Nature Genetics, August 22, 2024, 1914-1924

bioRxiv, 2025, nan

S8317

3BDO

3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signaling pathway. It inhibits autophagy in HUVECs. This compound inhibits oxLDL-induced apoptosis.

Cancer Immunology Research, May 02 2024, 631-643

Journal of Neuroscience, July 15 2020, 5531-5548

Cancer Immunology Research, 2024, 631–643